MedTrace Logo

Pharmacokinetic and Pharmacodynamic of Rocuronium

NCT02376595 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2015-03-03

No results posted yet for this study

Summary

The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.

Conditions

  • Neuromuscular Blockade

Interventions

DRUG

Rocuronium Bromide

Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.

Sponsors & Collaborators

  • Pontificia Universidad Catolica de Chile

    lead OTHER

Principal Investigators

  • Luis I Cortinez, MD · Ponticia Universidad Católica

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-11-30
Completion
2015-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02376595 on ClinicalTrials.gov